These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27329033)

  • 1. Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End.
    Wasylishen AR; Lozano G
    Cold Spring Harb Perspect Med; 2016 Aug; 6(8):. PubMed ID: 27329033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Roles of MDM2 and MDMX in Cancer.
    Karni-Schmidt O; Lokshin M; Prives C
    Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
    Wade M; Wahl GM
    Mol Cancer Res; 2009 Jan; 7(1):1-11. PubMed ID: 19147532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
    Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
    Toledo F; Wahl GM
    Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
    Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
    Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
    Toledo F; Wahl GM
    Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
    Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
    Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
    Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
    Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Lane DP
    Br J Cancer; 1999 Jul; 80 Suppl 1():1-5. PubMed ID: 10466753
    [No Abstract]   [Full Text] [Related]  

  • 11. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
    Qi DL; Cobrinik D
    Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA Control of p53.
    Liu J; Zhang C; Zhao Y; Feng Z
    J Cell Biochem; 2017 Jan; 118(1):7-14. PubMed ID: 27216701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 mutation "gradient effect" and its clinical implications.
    Zambetti GP
    J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
    Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
    Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of the p53-mediated stress response by MDM2 and MDM4.
    Perry ME
    Cold Spring Harb Perspect Biol; 2010 Jan; 2(1):a000968. PubMed ID: 20182601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for screening tumors for p53 status and therapeutic exploitation.
    Tullo A; D'Erchia AM; Sbisà E
    Expert Rev Mol Diagn; 2003 May; 3(3):289-301. PubMed ID: 12779005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
    Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
    Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome Stability Requires p53.
    Eischen CM
    Cold Spring Harb Perspect Med; 2016 Jun; 6(6):. PubMed ID: 27252396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
    Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
    Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.